Immunohistochemical characterization of prototypical endometrial clear cell carcinoma-diagnostic utility of HNF-1β and oestrogen receptor

Histopathology

Volumn 64, Issue 4, 2014, Pages 585-596

  Hoang, Lien N ^a   Han, Guangming ^b   Mcconechy, Melissa ^a,c   Lau, Sherman ^a   Chow, Christine ^a   Gilks, C Blake ^a   Huntsman, David G ^a,c   Köbel, Martin ^d   Lee, Cheng Han ^e  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Clear cell carcinoma; Endometrial cancer; Endometrioid carcinoma; HNF 1 ; Serous carcinoma; TP53

Indexed keywords

CLEAR CELL CARCINOMA; ENDOMETRIAL CANCER; ENDOMETRIOID CARCINOMA; HNF-1Β; SEROUS CARCINOMA; TP53;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; DIAGNOSIS, DIFFERENTIAL; ENDOMETRIAL NEOPLASMS; FEMALE; HEPATOCYTE NUCLEAR FACTOR 1-BETA; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN NEOPLASMS; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84895069346     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12286     Document Type: Article

References (33)

1. Fadare O, Parkash V, Dupont WD et al. The diagnosis of endometrial carcinomas with clear cells by gynecologic pathologists: an assessment of interobserver variability and associated morphologic features. Am. J. Surg. Pathol. 2012; 36; 1107-1118.
2. Gilks CB, Oliva E, Soslow RA. Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. Am. J. Surg. Pathol. 2013; 37; 874-881.
3. Hoang LN, McConechy MK, Koebel M et al. Histotype-genotype correlation in 36 high-grade endometrial carcinomas. Am. J. Surg. Pathol. 2013; 37; 1421-1432.
4. Bartosch C, Manuel Lopes J, Oliva E. Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features. Adv. Anat. Pathol. 2011; 18; 415-437.
5. Lomo L, Nucci MR, Lee KR et al. Histologic and immunohistochemical decision-making in endometrial adenocarcinoma. Mod. Pathol. 2008; 21; 937-942.
6. Soslow RA. Endometrial carcinomas with ambiguous features. Semin. Diagn. Pathol. 2010; 27; 261-273.
7. Han G, Sidhu D, Duggan MA et al. Reproducibility of histological cell type in high-grade endometrial carcinoma. Mod. Pathol. 2013; doi: 10.1038/modpathol.2013.102.
8. Greggi S, Mangili G, Scaffa C et al. Uterine papillary serous, clear cell, and poorly differentiated endometrioid carcinomas: a comparative study. Int. J. Gynecol. Cancer 2011; 21; 661-667.
9. Amant F, Moerman P, Neven P et al. Treatment modalities in endometrial cancer. Curr. Opin. Oncol. 2007; 19; 479-485.
10. Soslow RA, Bissonnette JP, Wilton A et al. Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences. Am. J. Surg. Pathol. 2007; 31; 979-987.
11. McMeekin DS, Filiaci VL, Thigpen JT et al. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. Gynecol. Oncol. 2007; 106; 16-22.
12. Tan DS, Miller RE, Kaye SB. New perspectives on molecular targeted therapy in ovarian clear cell carcinoma. Br. J. Cancer 2013; 108; 1553-1559.
13. Kandoth C, Schultz N, Cherniack AD et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497; 67-73.
14. McConechy MK, Ding J, Cheang MC et al. Use of mutation profiles to refine the classification of endometrial carcinomas. J. Pathol. 2012; 228; 20-30.
15. Fadare O, Liang SX. Diagnostic utility of hepatocyte nuclear factor 1-beta immunoreactivity in endometrial carcinomas: lack of specificity for endometrial clear cell carcinoma. Appl. Immunohistochem. Mol. Morphol. 2012; 20; 580-587.
16. Fadare O, Gwin K, Desouki MM et al. The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium. Mod. Pathol. 2013; 26; 1101-1110.
17. Wiegand KC, Shah SP, Al-Agha OM et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N. Engl. J. Med. 2010; 363; 1532-1543.
18. Yamamoto S, Tsuda H, Aida S et al. Immunohistochemical detection of hepatocyte nuclear factor 1 beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium. Hum. Pathol. 2007; 38; 1074-1080.
19. Fadare O, Renshaw IL, Liang SX. Does the loss of ARID1A (BAF-250a) expression in endometrial clear cell carcinomas have any clinicopathologic significance? A pilot assessment. J. Cancer 2012; 3; 129-136.
20. Wiegand KC, Lee AF, Al-Agha OM et al. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J. Pathol. 2011; 224; 328-333.
21. Tsuchiya A, Sakamoto M, Yasuda J et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am. J. Pathol. 2003; 163; 2503-2512.
22. Munksgaard PS, Blaakaer J. The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations. Gynecol. Oncol. 2012; 124; 164-169.
23. Yamamoto S, Tsuda H, Takano M et al. PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma. J. Pathol. 2011; 225; 189-194.
24. Kobel M, Kalloger SE, Carrick J et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am. J. Surg. Pathol. 2009; 33; 14-21.
25. DeLair D, Oliva E, Kobel M et al. Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases. Am. J. Surg. Pathol. 2011; 35; 36-44.
26. Hammond MEH, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch. Pathol. Lab. Med. 2010; 134; 48-72.
27. Kobel M, Reuss A, Bois A et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J. Pathol. 2010; 222; 191-198.
28. Anglesio MS, Carey MS, Kobel M et al. Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecol. Oncol. 2011; 121; 407-415.
29. Zorn KK, Bonome T, Gangi L et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin. Cancer Res. 2005; 11; 6422-6430.
30. Kalloger SE, Kobel M, Leung S et al. Calculator for ovarian carcinoma subtype prediction. Mod. Pathol. 2011; 24; 512-521.
31. Kao YC, Lin MC, Lin WC et al. Utility of hepatocyte nuclear factor-1β as a diagnostic marker in ovarian carcinomas with clear cells. Histopathology 2012; 61; 760-768.
32. An HJ, Logani S, Isacson C et al. Molecular characterization of uterine clear cell carcinoma. Mod. Pathol. 2004; 17; 530-537.
33. Lax SF, Pizer ES, Ronnett BM, Kurman RJ. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum. Pathol. 1998; 29; 551-558.